Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.40 |
| ▸ | RAB9A | P51151 | 9/20 | 0.40 |
| ▸ | MEN1 | O00255 | 9/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935926 | 1.00 | MAPT (0.40) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3944217 | 0.96 | RAB9A (0.39) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3944222 | 0.96 | RAB9A (0.39) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3934298 | 0.96 | P2RX5 (0.41) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3934301 | 0.96 | P2RX5 (0.41) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3934549 | 0.91 | P2RX5 (0.40) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3934552 | 0.91 | P2RX5 (0.40) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3943056 | 0.89 | MAPT (0.41) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3943061 | 0.89 | MAPT (0.41) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL3939358 | 0.89 | RAB9A (0.42) | MAPTRAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551830-B1 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-7148249-B2 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-12-12 | — | — | US | disclosed |
| EP-1551830-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004026829-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054710-A1 | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | CDK1, CDK2, CDK3 | MAPT 1798/4885RAB9A 3709/4885MEN1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.